BerGenBio presents preliminary clinical data from Phase II combination trial of bemcentinib and LDAC in elderly AML patients at ASH 2019
· Phase II trial evaluating bemcentinib in combination with low-dose cytarabine (LDAC) in elderly AML patients unfit for intensive therapy is well tolerated and shows promising efficacy · Long duration of response (>9.9 mo, still maturing) with 50% CR/CRi in 6 evaluable newly diagnosed patients receiving the bemcentinib-LDAC combination. · Clinical benefit demonstrated in >2L relapsed and refractory AML patients with 1 CR/CRi and 3 SD out of 6 evaluable patients · Pretreatment sAXL holds as predictive of response Bergen, Norway, December 9, 2019 – BerGenBio ASA (OSE:BGBIO), a